文献速递免疫规划传染病防控与疫情报告

丹麦与瑞典MMR疫苗复种与感染住院的间断时间序列分析

Revaccination with measles-mumps-rubella vaccine and hospitalization for infection in Denmark and Sweden - An interrupted time-series analysis.
PubMed 文献 · Vaccine · 2021-01-29

该研究采用间断时间序列分析,评估丹麦4岁和瑞典7-9岁儿童引入MMR复种对感染住院率的影响。结果显示丹麦4岁儿童发生率比为1.07(95%CI 0.89-1.28),瑞典7-9岁儿童为0.89(95%CI 0.77-1.02),加对照分析结果类似。结论为研究把握度不足,无法证实或否定此前个体水平研究的关联。

要点

  • 丹麦4岁儿童MMR复种后感染住院发生率比1.07(95%CI 0.89-1.28)。
  • 瑞典7-9岁儿童MMR复种后发生率比0.89(95%CI 0.77-1.02)。
  • 研究把握度不足,无法证实或否定既往个体水平研究结论。

核心结论

  • 该人群水平研究把握度不足,无法证实或否定丹麦个体水平研究中MMR复种与感染住院率降低的关联。

研究设计与样本

  • 间断时间序列分析,纳入丹麦4岁儿童和瑞典7-9岁儿童,使用全国医院登记数据,以泊松回归估计MMR复种引入后感染住院发病率变化,并调整季节性。
  • 丹麦MMR复种于2008年春季引入,瑞典于2009年秋季引入,当时麻疹、腮腺炎和风疹病例几乎为零。
  • 设置对照序列:丹麦3岁儿童和瑞典4岁儿童。

主要发现

  • 无对照分析中,丹麦4岁儿童感染住院(持续2天及以上)发生率比为1.07(95%CI 0.89-1.28)。
  • 无对照分析中,瑞典7-9岁儿童感染住院(持续2天及以上)发生率比为0.89(95%CI 0.77-1.02)。
  • 加对照分析结果与无对照分析类似。

临床怎么用

  • 该研究未提供足够证据支持或反对将MMR复种作为降低儿童感染住院率的群体层面干预措施。

局限性

  • 研究把握度不足,无法确认或排除MMR复种与感染住院率之间的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In a previous cohort study of 4-year-old Danish children, revaccination with the live measles-mumps-rubella vaccine (MMR) was associated with a 16% reduction in the rate of hospitalization lasting two days or longer for non-measles-mumps-rubella infections. AIM: To examine if the introduction of revaccination with MMR at 4 years of age in Denmark (spring 2008) and at 7-9 years of age in Sweden (autumn 2009), at a time when there was virtually no measles, mumps or rubella cases, was associated with a reduction in the rate of hospitalization-for-infection lasting two days or longer at the population level. METHODS: We included 4-year-olds in Denmark and 7-9-year-olds in Sweden. We obtained the number of hospitalization-for-infection lasting two days or longer from nationwide hospital registers. Person-years at risk were approximated from population statistics for each season and year. We performed an interrupted time series analysis using Poisson regression to estimate the change in hospitalization incidence rates following the introduction of MMR revaccination, adjusting for seasonality. We also performed analyses with control series (3-year-olds in Denmark and 4-year-olds in Sweden). RESULTS: Comparing the incidence of hospitalization-for-infection lasting two days or longer after the introduction of MMR revaccination with the expected level without an introduction of MMR revaccination resulted in an incidence rate ratio of 1.07 (95% confidence interval [CI] = 0.89-1.28) for 4-year-olds in Denmark and 0.89 (95% CI = 0.77-1.02) for 7-9-year-olds in Sweden in analyses without controls. Analyses with controls gave similar results. CONCLUSION: This population-level study of the introduction of MMR revaccination in Denmark and Sweden had inadequate power to confirm or refute the findings from an individual-level Danish study of an association between MMR revaccination and a lower incidence rate of hospitalization-for-infection lasting two days or longer.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sørup S, Englund H, Laake I, et al. Revaccination with measles-mumps-rubella vaccine and hospitalization for infection in Denmark and Sweden - An interrupted time-series analysis. Vaccine. 2021. PMID: 33518465. doi:10.1016/j.vaccine.2021.01.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。